rAAV-mediated long-term liver-generated expression of an angiogenesis inhibitor can restrict renal tumor growth in mice

Cancer Research

Volumn 62, Issue 11, 2002, Pages 3077-3083

  Davidoff, Andrew M ^a   Nathwani, Amit C ^a   Spurbeck, William W ^a   Ng, Catherine Y C ^a   Zhou, Junfang ^a   Vanin, Elio F ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; BASIC FIBROBLAST GROWTH FACTOR; BETA ACTIN; HEPARIN; MATRIGEL; RNA; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VIRUS VECTOR;

ADENO ASSOCIATED VIRUS; ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CELL ACTIVATION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFICACY; EMBRYO; ENDOTHELIUM CELL; GENE THERAPY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; KIDNEY TUMOR; MOUSE; NONHUMAN; PRIORITY JOURNAL; SCID MOUSE; TRANSGENE; TUMOR GROWTH; TUMOR VASCULARIZATION;

ANIMALS; CELL DIVISION; DEPENDOVIRUS; ENDOTHELIAL GROWTH FACTORS; ENDOTHELIUM, VASCULAR; GENE THERAPY; HUMANS; KIDNEY NEOPLASMS; LIVER; LYMPHOKINES; MICE; MICE, SCID; NEOVASCULARIZATION, PATHOLOGIC; PROTO-ONCOGENE PROTEINS; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTORS, GROWTH FACTOR; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; TRANSDUCTION, GENETIC; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1; VASCULAR ENDOTHELIAL GROWTH FACTORS; WILMS TUMOR; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 0036606007     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Mechanisms and therapeutic implications of angiogenesis
2. Tumor-associated angiogenesis: Mechanisms, clinical implications, and therapeutic strategies
3. Antiangiogenic gene therapy
4. Gene therapy strategies for tumor antiangiogenesis
5. Antiangiogenic gene therapy
6. Gene therapy for antiangiogenesis
7. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity
8. Progress in antiangiogenic gene therapy of cancer
9. Adeno-associated virus for cancer gene therapy
10. Adeno-associated virus-mediated delivery of antiangiogenic factors as an antitumor strategy
11. Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovirus
12. Highly purified recombinant adeno-associated virus vectors are biologically active and free of detectable helper and wild-type viruses
13. Adeno-associated virus as a vector for liver-directed gene therapy
14. Factors influencing in vivo transduction by recombinant adeno-associated viral vectors expressing the human factor IX cDNA
15. Sustained correction of bleeding disorder in hemophilia B mice by gene therapy
16. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis
17. The regulation of blood vessel growth by vascular endothelial growth factor
18. Vascular permeability factor/vascular endothelial growth factor and the significance of microvascular hyperpermeability in angiogenesis
19. Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant
20. Inhibition of tumor growth by targeting tumor endothelium using a soluble vascular endothelial growth factor receptor
21. Gene therapy-mediated expression by tumor cells of the angiogenesis inhibitor flk-1 results in inhibition of neuroblastoma growth in vivo
22. Retroviral vector-producer cell mediated angiogenesis inhibition restricts neuroblastoma growth in vivo
23. Bone marrow-derived cells contribute to tumor neovasculature and, when modified to express an angiogenesis inhibitor, can restrict tumor growth in mice
24. Vascular endothelial growth factor and platelet-derived growth factor are potential angiogenic and metastatic factors in human breast cancer
25. Vegf, Vegf-B, Vegf-C, and their receptors KDR, FLT-1, and FLT-4 during the neoplastic progression of human colonic mucosa
26. Efficient selection for high-expression transfectants with a novel eukaryotic vector
27. A recombinant plasmid from which an infectious adeno-associated virus genome can be excised in vitro and its use to study viral replication
28. Efficient gene transfer into human cord blood CD34+ cells and the CD34+
29. The kinetics of rAAV integration in the liver
30. Genetic heterogeneity of angiogenesis in mice
31. Treatment of children with stages II to IV anaplastic Wilms' tumor: A report from the National Wilms' Tumor Study Group
32. Rhabdoid tumor of kidney. A report of 111 cases from the National Wilms' Tumor Study Pathology Center
33. Metastasis correlates with production of vascular endothelial growth factor in a murine model of human Wilms' tumor
34. Angiogenesis and angiogenic growth factors in Wilms' tumor
35. Anti-VEGF antibody suppresses primary tumor growth and metastasis in an experimental model of Wilms' tumor
36. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene
37. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele
38. Definition of two angiogenic pathways by distinct α v integrins
39. Expression and functional significance of vascular endothelial growth factor receptors in human tumor cells